|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Product revenue, net | |||||
| Operating expenses: | |||||
| Cost of sales | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Settlement expense related to Melucci litigation | |||||
| Insurance recovery related to Melucci litigation | |||||
| Total operating expenses | |||||
| Income from operations | |||||
| Interest and other income | |||||
| Income before income taxes | |||||
| Income tax benefit (expense) | |||||
| Net income | |||||
| Net unrealized (loss) gain on available-for-sale investments, net of tax impact of $198, $15 and $(104) | |||||
| Foreign currency translation (loss) gain, net of tax | |||||
| Total comprehensive income | |||||
| Net income attributable to common stockholders, basic | |||||
| Net income attributable to common stockholders, diluted | |||||
| Basic net income per share (in dollars per share) | |||||
| Diluted net income per share (in dollars per share) | |||||
| Weighted-average shares outstanding used in computing net income per common share | |||||
| Basic (in shares) | |||||
| Diluted (in shares) |
Loading...